

# Judy Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9474251/publications.pdf>

Version: 2024-02-01

4  
papers

121  
citations

1937685

4  
h-index

2272923

4  
g-index

4  
all docs

4  
docs citations

4  
times ranked

115  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>p53</i> . <i>Clinical Cancer Research</i> , 2021, 27, 5236-5247.	7.0	74
2	Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. <i>Clinical Cancer Research</i> , 2021, 27, 1864-1874.	7.0	20
3	Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , 2021, 27, 3602-3609.	7.0	20
4	Reversible HER2 antibody-drug conjugate-induced ocular toxicity. <i>Canadian Journal of Ophthalmology</i> , 2021, , .	0.7	7